BioXcel Therapeutics's quarterly market cap
declined
from Sep. 2025 ($51.19 Mil) to Dec. 2025 ($35.72 Mil) but then
increased
from Dec. 2025 ($35.72 Mil) to Mar. 2026 ($36.28 Mil).
BioXcel Therapeutics's annual market cap
declined
from Dec. 2023 ($88.31 Mil) to Dec. 2024 ($18.56 Mil) but then
increased
from Dec. 2024 ($18.56 Mil) to Dec. 2025 ($35.72 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioXcel Therapeutics's Enterprise Value for Today is $125.72 Mil.
BioXcel Therapeutics (NAS:BTAI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioXcel Therapeutics Market Cap Related Terms
BioXcel Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioXcel Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BTAI) has a Market Cap of $42.61 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioXcel Therapeutics and its competitors. According to the industry distribution chart, BioXcel Therapeutics ranks #713 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 69.8%.
Is BioXcel Therapeutics' Market Cap too high?
BioXcel Therapeutics' current Market Cap is $42.61 Mil. The Drug Manufacturers industry median Market Cap is 210.16. BioXcel Therapeutics' value of $42.61 Mil is 79.7% below this industry median. Based on the distribution chart, BioXcel Therapeutics ranks #713 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioXcel Therapeutics has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Market Cap compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #713 out of 1022 companies for Market Cap. This places BioXcel Therapeutics in the lower half of its industry. The industry median Market Cap is 210.16. BioXcel Therapeutics' value of $42.61 Mil is 79.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioXcel Therapeutics's current Market Cap of $42.61 Mil is 79.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioXcel Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current Market Cap is $42.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.38 — trading 106% above its estimated fair value. The current Market Cap is $42.61 Mil and 79.7% below the Drug Manufacturers industry median of 210.16. BioXcel Therapeutics' overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Market Cap is $42.61 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (BTAI) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of $1.38 is trading 106% above its estimated GF Value™ of $0.67.
GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.
Key valuation signals for BTAI:
Market Cap: $42.61 Mil
GF Value™: $0.67 vs. price of $1.38 (106% above fair value)
Industry Position: 79.7% below the Drug Manufacturers median (#713 of 1022)
No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
14GF Score
Get the complete analysis for BTAI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAI has been successfully added to your 
